Wave Life Sciences (WVE) Research & Development (2014 - 2026)
Wave Life Sciences' (WVE) quarterly Research & Development came in at $51.3 million in Q2 2026, up 18.0% YoY from $43.5 million in Q2 2025, and up 8.12% on a QoQ basis from $47.4 million in Q1 2026.
Wave Life Sciences (WVE) Research & Development (2014 - 2026) Analysis & Trends
Wave Life Sciences (WVE) has 13 years of Research & Development data on file, last reported at $51.3 million in Q2 2026.
- Quarterly Research & Development rose 18.0% year-over-year to $51.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $197.4 million (up 16.18% YoY) and the FY2025 annual result came in at $182.8 million, up 14.46% from the prior year.
- Research & Development rose to $51.3 million in Q2 2026, from $47.4 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $52.8 million in Q4 2025 to a low of $27.5 million in Q1 2022.
- A 5-year average of $38.2 million and a median of $37.2 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development fell 17.74% — and 2024, when it surged 31.02%.
- Tracing WVE's Research & Development over 5 years: stood at $31.1 million in 2022, then rose by 9.64% to $34.1 million in 2023, then surged by 31.02% to $44.6 million in 2024, then advanced by 18.3% to $52.8 million in 2025, then declined by 2.88% to $51.3 million in 2026.
- The last three Research & Development figures came in at $51.3 million (Q2 2026), $47.4 million (Q1 2026), and $52.8 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Wave Life Sciences | 1.05 Bn | 677.62 Mn | - | 51.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 51.29 Mn |
| Mar 31, 2026 | 47.44 Mn |
| Dec 31, 2025 | 52.81 Mn |
| Sep 30, 2025 | 45.87 Mn |
| Jun 30, 2025 | 43.47 Mn |
| Mar 31, 2025 | 40.62 Mn |
| Dec 31, 2024 | 44.65 Mn |
| Sep 30, 2024 | 41.20 Mn |
| Jun 30, 2024 | 40.39 Mn |
| Mar 31, 2024 | 33.45 Mn |
| Dec 31, 2023 | 34.07 Mn |
| Sep 30, 2023 | 31.64 Mn |
| Jun 30, 2023 | 33.31 Mn |
| Mar 31, 2023 | 30.98 Mn |
| Dec 31, 2022 | 31.08 Mn |
| Sep 30, 2022 | 27.58 Mn |
| Jun 30, 2022 | 29.73 Mn |
| Mar 31, 2022 | 27.47 Mn |
| Dec 31, 2021 | 25.76 Mn |
| Sep 30, 2021 | 31.09 Mn |